FY2026 Earnings Estimate for ABEO Issued By HC Wainwright

Abeona Therapeutics Inc. (NASDAQ:ABEO – Free Report) – HC Wainwright boosted their FY2026 earnings per share estimates for shares of Abeona Therapeutics in a note issued to investors on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings of ($0.96) per share for the year, up from their prior estimate of ($1.15). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q4 2026 earnings at ($0.22) EPS, Q1 2027 earnings at ($0.24) EPS, Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.20) EPS, Q4 2027 earnings at ($0.17) EPS and FY2027 earnings at ($0.82) EPS.

A number of other analysts have also recently commented on the stock. Oppenheimer restated an “outperform” rating and set a $21.00 price target (down from $22.00) on shares of Abeona Therapeutics in a research note on Friday, August 14th. UBS Group reiterated a “buy” rating on shares of Abeona Therapeutics in a research note on Friday, September 25th. Roth Capital started coverage on shares of Abeona Therapeutics in a research note on Thursday, September 17th. They issued a “buy” rating and a $17.00 price objective for the company. Wall Street Zen raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings downgraded Abeona Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, November 10th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Abeona Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Get Our Latest Analysis on Abeona Therapeutics

Abeona Therapeutics Price Performance

ABEO opened at $2.60 on Monday. The firm has a 50-day moving average price of $4.57 and a 200-day moving average price of $5.37. Abeona Therapeutics has a twelve month low of $2.09 and a twelve month high of $7.65. The company has a market capitalization of $148.59 million, a price-to-earnings ratio of -2.43 and a beta of 1.50.

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.09. The business had revenue of $13.49 million for the quarter, compared to the consensus estimate of $14.82 million. Abeona Therapeutics had a negative net margin of 160.30% and a negative return on equity of 44.82%.

Insiders Place Their Bets

In other news, CEO Vishwas Seshadri sold 19,608 shares of the company’s stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $5.16, for a total transaction of $101,177.28. Following the sale, the chief executive officer directly owned 1,286,500 shares in the company, valued at $6,638,340. This represents a 1.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Joseph Vazzano sold 9,191 shares of the stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $5.16, for a total transaction of $47,425.56. Following the completion of the sale, the chief financial officer directly owned 482,888 shares in the company, valued at approximately $2,491,702.08. The trade was a 1.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 55,428 shares of company stock worth $296,508 over the last quarter. Insiders own 7.10% of the company’s stock.

Hedge Funds Weigh In On Abeona Therapeutics

Several hedge funds have recently bought and sold shares of ABEO. Global Retirement Partners LLC boosted its holdings in Abeona Therapeutics by 1,026.2% in the 3rd quarter. Global Retirement Partners LLC now owns 4,978 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 4,536 shares during the period. Nan Fung Trinity HK Ltd. grew its position in shares of Abeona Therapeutics by 336.6% during the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 552,270 shares of the biopharmaceutical company’s stock valued at $2,899,000 after purchasing an additional 425,770 shares in the last quarter. AIGH Capital Management LLC bought a new position in shares of Abeona Therapeutics in the third quarter worth $15,225,000. Simplify Asset Management Inc. bought a new position in shares of Abeona Therapeutics in the third quarter worth $1,451,000. Finally, WINTON GROUP Ltd bought a new position in shares of Abeona Therapeutics in the second quarter worth $256,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

(Get Free Report)

Abeona Therapeutics, Inc. is a biotechnology company focused on developing cell and gene therapies for serious and rare diseases. Its work includes treatments designed to address the underlying genetic causes of disease. The company’s lead product, ZEVASKYN (prademagene zamikeracel), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited skin disorder. Made from a patient’s skin cells, the therapy uses genetic modification to help cells produce type VII collagen and is applied to wounds.

Read More

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.